HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Researchers intensify efforts to solve mysteries of exceptional responders
-
- Velimogene aliplasmid, T-VEC studies put intralesional immunotherapy into perspective Vernon K. Sondak, MD
- Union calls for immediate regulation of e-cigarette products
- A 72-year-old man develops engraftment syndrome after autologous HSCT Tim McCarthy, MD
- FDA approves Nexavar for differentiated thyroid cancer
- FDA warns genetic testing service to halt sales, seek formal approval
- More high-risk women underwent breast MRI, but improvement still needed
- Childhood cancer survivors have high frailty rates as young adults
- Symptom clusters predicted poor outcomes after surgery for esophageal cancer
-
- IDSA guidelines urge vaccinations for immunocompromised patients
- More than a quarter of adults not current with colorectal cancer screening
- Benefits of ziv-aflibercept plus FOLFIRI observed across subgroups of patients with pretreated metastatic colorectal cancer
- Cancer society: Racial disparities in breast cancer survival persist
- Chemotherapy with fluorouracil or gemcitabine may be optimal adjuvant therapy for pancreatic cancer
- Consumption of sugar-sweetened beverages increased endometrial cancer risk
- Elevated plasma vitamin B12 levels increased risk for cancer
- Extent of surgery requires individualization in medullary thyroid cancer
-
- Greater visceral fat increased risk for cancer among older adults
- Induction chemotherapy did not improve outcomes in HNSCC
- IOF releases position paper on fracture prevention for patients with cancer-associated bone disease
- One dose of HPV vaccine protected against cervical cancer for 4 years
- Oropharyngeal cancer burden increased in younger individuals, developed countries
- Positive surgical margins linked with adverse survival-related outcomes in soft tissue sarcoma patients
- SLNB after neoadjuvant breast cancer therapy not yet viable management strategy
- Statin use reduced prostate cancer, all-cause mortality
-
- ASCO elects 2015-16 president
- Cancer center VP elected to IOM
- Center’s founding director steps down
- Medical director named for Dana-Farber satellite
- Researcher named institute director
- UC Davis professor receives award
- Weill Cornell hires MPN center director
- Sotatercept shows promise for anemia in patients with beta-thalassemia
-
- Talimogene laherparepvec extended OS in metastatic melanoma
- Imetelstat induced complete remission in myelofibrosis
- Velimogene aliplasmid inferior to chemotherapy in advanced melanoma
- Addition of carboplatin, bevacizumab to neoadjuvant regimen increased response in triple-negative breast cancer
- Addition of gemtuzumab ozogamicin to chemotherapy improved EFS, prevented relapse in pediatric AML
- Anastrozole reduced breast cancer in high risk women by more than 50%
- Alternating, sequential combination drug administration feasible in elderly with multiple myeloma
- Bisphosphonate treatment did not benefit women with chemoresistant breast cancer
-
- Circulating tumor cell level after chemotherapy predicts OS
- Dasatinib may inhibit AI resistance in metastatic breast cancer
- Novel agent induced high response rate in high-risk CLL, SLL
- PIK3CA mutation predicted pCR in HER-2–positive breast cancer
- Ruxolitinib extended OS in myelofibrosis
- Surgery, radiation after chemotherapy offered no survival benefit in metastatic breast cancer
- Brentuximab vedotin induced long-term remissions in Hodgkin’s lymphoma
- Forced chromatin looping may reprogram gene expression in hemoglobinopathy
-
- Dexamethasone can provide short-term relief from cancer-related fatigue Lisa K. Lohr, PharmD, BCPS, BCOP